BACKGROUND AND OBJECTIVES: Roxadustat (FG-4592), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis, regulates iron metabolism, and reduces hepcidin, was evaluated in this phase 2b study for safety, efficacy, optimal dose, and dose frequency in patients with nondialysis CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The 145 patients with nondialysis CKD and hemoglobin ≤10.5 g/dl were randomized into one of six cohorts of approximately 24 patients each with varying roxadustat starting doses (tiered weight and fixed amounts) and frequencies (two and three times weekly) followed by hemoglobin maintenance with roxadustat one to three times weekly. Treatment duration was 16 or 24 weeks. Intravenous iron was prohibited. The primary end point was the proportion of patients achieving hemoglobin increase of ≥1.0 g/dl from baseline and hemoglobin of ≥11.0 g/dl by week 17 (16 weeks of treatment). Secondary analyses included mean hemoglobin change from baseline, iron utilization, and serum lipids. Safety was evaluated by frequency/severity of adverse events. RESULTS: Of the 145 patients enrolled, 143 were evaluable for efficacy. Overall, 92% of patients achieved hemoglobin response. Higher compared with lower starting doses led to earlier achievement of hemoglobin response. Roxadustat-induced hemoglobin increases were independent of baseline C-reactive protein levels and iron repletion status. Overall, over the first 16 treatment weeks, hepcidin levels decreased by 16.9% (P=0.004), reticulocyte hemoglobin content was maintained, and hemoglobin increased by a mean (±SD) of 1.83 (±0.09) g/dl (P<0.001). Overall mean total cholesterol level was reduced by a mean (±SD) of 26 (±30) mg/dl (P<0.001) after 8 weeks of therapy, independent of the use of statins or other lipid-lowering agents. No drug-related serious adverse events were reported. CONCLUSIONS: In patients with nondialysis CKD who were anemic, various starting dose regimens of roxadustat were well tolerated and achieved anemia correction with reduced serum hepcidin levels. After anemia correction, hemoglobin was maintained by roxadustat at various dose frequencies without intravenous iron supplementation.
BACKGROUND AND OBJECTIVES: Roxadustat (FG-4592), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis, regulates iron metabolism, and reduces hepcidin, was evaluated in this phase 2b study for safety, efficacy, optimal dose, and dose frequency in patients with nondialysis CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The 145 patients with nondialysis CKD and hemoglobin ≤10.5 g/dl were randomized into one of six cohorts of approximately 24 patients each with varying roxadustat starting doses (tiered weight and fixed amounts) and frequencies (two and three times weekly) followed by hemoglobin maintenance with roxadustat one to three times weekly. Treatment duration was 16 or 24 weeks. Intravenous iron was prohibited. The primary end point was the proportion of patients achieving hemoglobin increase of ≥1.0 g/dl from baseline and hemoglobin of ≥11.0 g/dl by week 17 (16 weeks of treatment). Secondary analyses included mean hemoglobin change from baseline, iron utilization, and serum lipids. Safety was evaluated by frequency/severity of adverse events. RESULTS: Of the 145 patients enrolled, 143 were evaluable for efficacy. Overall, 92% of patients achieved hemoglobin response. Higher compared with lower starting doses led to earlier achievement of hemoglobin response. Roxadustat-induced hemoglobin increases were independent of baseline C-reactive protein levels and iron repletion status. Overall, over the first 16 treatment weeks, hepcidin levels decreased by 16.9% (P=0.004), reticulocyte hemoglobin content was maintained, and hemoglobin increased by a mean (±SD) of 1.83 (±0.09) g/dl (P<0.001). Overall mean total cholesterol level was reduced by a mean (±SD) of 26 (±30) mg/dl (P<0.001) after 8 weeks of therapy, independent of the use of statins or other lipid-lowering agents. No drug-related serious adverse events were reported. CONCLUSIONS: In patients with nondialysis CKD who were anemic, various starting dose regimens of roxadustat were well tolerated and achieved anemia correction with reduced serum hepcidin levels. After anemia correction, hemoglobin was maintained by roxadustat at various dose frequencies without intravenous iron supplementation.
Authors: Maneesh Sud; Navdeep Tangri; Adeera Levin; Melania Pintilie; Andrew S Levey; David M Naimark Journal: Am J Kidney Dis Date: 2014-01-28 Impact factor: 8.860
Authors: Vandana Menon; Xuelei Wang; Tom Greene; Gerald J Beck; John W Kusek; Santica M Marcovina; Andrew S Levey; Mark J Sarnak Journal: Am J Kidney Dis Date: 2003-07 Impact factor: 8.860
Authors: Anupama Mohanram; Zhongxin Zhang; Shahnaz Shahinfar; William F Keane; Barry M Brenner; Robert D Toto Journal: Kidney Int Date: 2004-09 Impact factor: 10.612
Authors: Marc A Pfeffer; Emmanuel A Burdmann; Chao-Yin Chen; Mark E Cooper; Dick de Zeeuw; Kai-Uwe Eckardt; Jan M Feyzi; Peter Ivanovich; Reshma Kewalramani; Andrew S Levey; Eldrin F Lewis; Janet B McGill; John J V McMurray; Patrick Parfrey; Hans-Henrik Parving; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Robert Toto Journal: N Engl J Med Date: 2009-10-30 Impact factor: 91.245
Authors: J W Eschbach; M H Abdulhadi; J K Browne; B G Delano; M R Downing; J C Egrie; R W Evans; E A Friedman; S E Graber; N R Haley Journal: Ann Intern Med Date: 1989-12-15 Impact factor: 25.391
Authors: Simon D Roger; Francesco Locatelli; Rainer P Woitas; Maurice Laville; Sheldon W Tobe; Robert Provenzano; Thomas A Golper; Prajej Ruangkanchanasetr; Ho Yung Lee; Kwan-Dun Wu; Michal Nowicki; Agnes Ladanyi; Alberto Martínez-Castelao; Ulrich Beyer; Frank C Dougherty Journal: Nephrol Dial Transplant Date: 2011-04-19 Impact factor: 5.992
Authors: Xiaojia Huang; Xianming Zhang; David X Zhao; Jun Yin; Guochang Hu; Colin E Evans; You-Yang Zhao Journal: Am J Pathol Date: 2019-05-20 Impact factor: 4.307
Authors: Mehmet Kanbay; Mustafa C Bulbul; Sidar Copur; Baris Afsar; Alan A Sag; Dimitrie Siriopol; Masanari Kuwabara; Silvia Badarau; Adrian Covic; Alberto Ortiz Journal: J Nephrol Date: 2020-05-21 Impact factor: 3.902
Authors: Verena Petzer; Piotr Tymoszuk; Malte Asshoff; Joana Carvalho; Jonathan Papworth; Cecilia Deantonio; Luke Bayliss; Matthew Stephen Wake; Markus Seifert; Natascha Brigo; Lara Valente de Souza; Richard Hilbe; Philipp Grubwieser; Egon Demetz; Stefanie Dichtl; Chiara Volani; Sylvia Berger; Felix Böhm; Alexander Hoffmann; Christa Pfeifhofer-Obermair; Laura von Raffay; Sieghart Sopper; Stephanie Arndt; Anja Bosserhoff; Léon Kautz; Prunelle Perrier; Manfred Nairz; Dominik Wolf; Guenter Weiss; Volker Germaschewski; Igor Theurl Journal: Blood Date: 2020-08-27 Impact factor: 22.113